A trial fibrillation (AF) brings a high risk of mortality and associated morbidities, including stroke and heart failure (HF). [1] [2] [3] Considering our growing elderly population, AF is becoming an enormous public health challenge and up to 10% to 15% of 70 to 80 year olds will develop AF. [2] [3] [4] Current pharmacological AF treatment and prevention approaches are ineffective, and our understanding of the underlying mechanisms is incomplete, limiting the development of new therapeutic strategies.
no AF history, no history of major cardiovascular diseases, and lacking structural remodeling). Once one specific pathogenic pathway is established, defining and understanding the contributions of all the other AF-associated circumstances, stresses, and factors become possible.
JNK2 (JNK isoform 2) is a major isoform in the heart. 16 Our results reveal that JNK2 activation is markedly elevated in aged human, rabbit, and mouse atria. Further, this age-associated JNK2 activation causes abnormal intracellular calcium (Ca 2+ ) waves and diastolic sarcoplasmic reticulum (SR) Ca 2+ leak. It is well known that the action of CaMKII (Ca 2+ /calmodulin-dependent kinase II) on SR Ca 2+ mishandling (ie, diastolic Ca 2+ leak and waves) is proarrhythmic. [17] [18] [19] [20] [21] [22] Indeed, CaMKII inhibition has been considered as a potential antiarrhythmic intervention for HF. 23 Here, we discovered the JNK2/CaMKII crosstalk as a previously unknown molecular mechanism of CaMKII activation. Activated JNK2 directly phosphorylates CaMKII proteins, driving CaMKII proarrhythmic effects on diastolic SR Ca 2+ handling. In aged mice, JNK2 inhibition eliminated age-related CaMKII hyperactivation and the associated aberrant diastolic SR Ca 2+ leak, Ca 2+ waves, and AF susceptibility. These results identify JNK2 inhibition as a potential target in developing new therapeutic strategies to prevent or treat AF.
Methods
All data and supporting materials have been provided with the published article. An expanded Methods Section is available in the Online Data Supplement.
Animal and Cell Models
Wild-type (WT) C57B/6j male mice (Jackson Laboratory, ME) at 24 to 32 months (aged) and 2 to 2.5 months (young) were studied. Three mouse models were used to assess the contribution of JNK and CaMKII on Ca 2+ dynamics and AF genesis. They were (1) a cardiac-specific inducible MKK7D ( MAP kinase kinase 7) trangenic mouse strain (a generous gift from Dr Yibin Wang, University of California, Los Angeles [UCLA] ) that can express cardiac MKK7D to robustly activate JNK with tamoxifen treatment, 24 (2) homozygous JNK2KO (JNK2 knockout mice 25 [Mapk9tm1Flv/J]; Jackson Laboratory), and (3) AC3-I mice, 21 with cardiac-specific transgenic expression of a CaMKII peptide inhibitor. JNK2KO and AC3-I mice were treated with anisomycin as previously described. 8, 26 Young (6 months) and aged (60 months) New Zealand White male rabbits were also used. Four young rabbits were treated with a JNK activator anisomycin. 27 Rabbit atrial myocytes were isolated as previously described with modification. 17 All animal studies followed the Guide for the Care and Use of Laboratory Animals (National Institutes of Health Publication, 8th Edition, 2011) and were approved by the Institutional Animal Care and Use Committees of Rush University Medical Center, Loyola University Chicago, University of Alabama at Birmingham, and University of Iowa.
A well-characterized cultured myocyte line (HL-1, from Dr William Claycomb, Louisiana State University) was used for our studies as previously described. 7, 8, 26 Cells were treated with JNK activator anisomycin or infected with adenoviral JNK activator MKK7D to activate JNK in the presence or absence of JNK or CaMKII inhibition as described in the Online Data Supplement. 
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Novelty and Significance
What Is Known?
• Atrial fibrillation (AF) is the most common sustained arrhythmia and a major public health problem, which currently lacks effective pharmacological therapies.
• Advanced age is a major risk factor for AF. Consequently, the burden of AF is growing exponentially as the mean age of many populations around the world grows.
What New Information Does This Article Contribute?
• Kinase-on-kinase pathogenic crosstalk is critical in governing intercellular Ca 2+ signaling and consequently Ca
2+
-mediated atrial arrhythmias.
• Advancing age and other stresses (like alcohol, obesity, inflammation, etc.) drive JNK (c-Jun N-terminal kinase) activation and the JNK/ CaMKII (Ca 2+ /calmodulin-dependent kinase II) crosstalk is likely a critical mechanism that couples arrhythmia and these stresses.
• JNK2 inhibition may be a potential target in developing new therapeutic strategies to prevent or treat AF.
AF is associated with a high risk of mortality and associated morbidities, including stroke and heart failure. However, there is no clear molecular concept addressing the mechanism for enhanced atrial arrhythmogenicity in the aged heart. Here, we report that activation of the kinase JNK2 leads to arrhythmogenic diastolic Ca 2+ mishandling. Further, we found that JNK2 is a critical activator of CaMKII, a highly validated proarrhythmic signal, through direct phosphorylation of CaMKII. The phosphorylated and hyperactivated CaMKII ultimately drives the diastolic Ca 2+ dysfunction that triggers atrial arrhythmias. Our study reveals a previously unrecognized link between JNK2 activation and the age-related enhancement of AF propensity. This link involves a novel, previously unknown, form of pathogenic kinase-on-kinase crosstalk. Our studies reveal a new potential therapeutic target (JNK2) that can be leveraged to prevent the CaMKII hyperactivation and thus limit AF and potentially other cardiovascular diseases.
Human Atrial Specimens
Human right atrial tissues were obtained from donor hearts (Online Table I 
AF Induction in Mice In Vivo and in Human Atrial Preparations Ex Vivo
In vivo AF induction was conducted in sedated mice, and electrogram data were recorded using a 1.1F octapolar catheter inserted into the right atrium as previously described. 19 Ex vivo AF induction in human donor atria was performed as described in the Online Data Supplement.
Confocal Ca 2+ Imaging
Confocal line scanning Ca 2+ images were obtained from intact atrium or atrial myocytes as previously described. 28 Frequencies of Ca
2+
waves/sparks and time constant (τ) of Ca 2+ decay were analyzed from intrinsic sinus rhythm and recovered beats after the burst pacing (5-10 Hz) as previously described. [28] [29] [30] Tetracaine-sensitive SR Ca 2+ leak was measured using our well-established protocols as previously described.
17,29,31
Intact Atrial Optical Mapping
Intact mouse hearts were preloaded with Rhod2-AM (5 µmol/L) followed by Rh237 (10 mmol/L; Invitrogen). V m and Ca 2+ signals were simultaneously recorded using a dual-channel optical imaging system as previously described. 7, 26 The SD of the difference between the activation time of action potential and calcium transient (Δt Vm−Ca ) for a total of 400 channels within the mapping field was calculated to reflect the heterogeneity of the relationship between V m and Ca 2+ signals as previously described.
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Single RyR2 Recording
Single RyR channel function was measured by fusing isolated WT mouse SR vesicles into lipid bilayers as previously described. 33 Anisomycin, alkaline phosphatase, 17 the CaMKII inhibitors KN93 17 and AIP, and the JNK2-specific inhibitor JNK2I-IX were applied to the cytosolic side of the reconstituted RyR2 (ryanodine receptor) channels.
CaMKII Activity Biosensor Imaging
The adenoviral mutant variant CaMKII sensor, Camui-vv (Förster resonance energy transfer [FRET]-based CaMKII sensor with mutated Met280Val & Met281Val; lacking the oxidation M280/M281 site but containing the intact autophosphorylation Thr286 site), was used to quantify the contribution of CaMKII phosphorylation and oxidation on CaMKII activation in anisomycin-treated isolated rabbit myocytes as previously described.
34
Biochemical Assays
Immunoblotting was performed as previously described. 8, 17 Protein expressions were detected using specific antibodies, and JNK2 immunoprecipitation was also conducted using a JNK2-specific antibody as previously described. 17 Human influenza hemagglutinin (HA)-tagged WT CaMKII-WT and mutant CaMKII-T286A vectors were constructed as previously described to determine the direct action of JNK2 on CaMKII phosphorylation, detected by immunoblotting and ADP-Glo Kinase assay (Promega), per manufacturer's instructions. 34 
Statistical Analysis
All data are presented as mean±SEM. Differences between multiple groups or any 2 groups were evaluated using 1-way ANOVA with post hoc Tukey test or Student t test. When heterogeneity of variance was evidenced, a nonparametric Mann-Whitney test or nonparametric 1-way ANOVA was performed. A P value <0.05 was considered to be significant.
Results
JNK Activation and AF Susceptibility
As age increased, human atria showed markedly enhanced activation of JNK (JNK-P [phosphorylated JNK]), as assessed by immunoblotting ( Figure 1A ). This trend persisted when JNK-P was normalized to either unchanged total JNK2 proteins ( Figure 1B ; Online Figure IA and IB) or JNK1 (data not shown). Although we found unchanged total JNK proteins, JNK1 and JNK2 mRNA expression were also unchanged in human atria with increasing age (Online Figure IC and ID) . The human atria were obtained from hearts of donors without a history of AF or major cardiovascular disease (Online Table I ). We also measured AF inducibility in Langendorffperfused human donor heart atrial preparations challenged with electric burst pacing. Three out of 4 aged donor hearts showed pacing-induced AF events after a train of electric stimulation. Figure 1C shows pacing-induced AF in 2 aged atrial preps subjected to 1 and 3 Hz pacing, respectively (30 s, 2× diastolic threshold; Figure 1C , long red arrows; n=4). In contrast, no pacing-induced AF events were found in any of the 4 young controls (even at a higher pacing frequency 4 Hz; Figure 1D ; n=4).
Like human atria, aged WT mouse atria also had elevated JNK-P (Figure 2A ), and this was associated with a dramatically increased propensity for pacing-induced AF 19 (Figure 2B through 2D) compared with that of young controls. These aged mice showed preserved cardiac function and an unchanged amount of atrial interstitial fibrosis (quantified using Trichrome staining as previously described 30 ; Online Figure  IIA and IIB) compared with young controls. A JNK2-specific inhibitor (JNK2I-IX with no action on JNK1 or other MAP kinases 35 ) abolished pacing-induced AF when applied to WT aged mice ( Figure 2B , right bar). When induced with tamoxifen, cardiac-specific MKK7D transgenic mice 24 expressed constitutively active MKK7, an upstream JNK activator. 5 In these mice, JNK activation was significantly increased by tamoxifen treatment ( Figure 2E ). The cardiac function of the MKK7D mice was the same before and 5 days after treatment (Online Figure IIC) . In young MKK7D mice, induction of JNK activation resulted in an increased incidence of pacinginduced AF (n=4/5 versus 0/6 tamoxifen-treated WT littermates; Figure 2F and 2G). Thus, JNK activation promotes AF initiation in young mice similar to the action of age-associated JNK activation in aged WT mice.
JNK Activation and Abnormal Ca 2+ Activities
Confocal Ca 2+ imaging in Langendorff-perfused intact aged WT mouse atria revealed that there were frequent Ca 2+ waves during the intrinsic sinus rhythm, but even more waves were evidenced after a bout of rapid electric pacing ( Figure 3A and 3B). The Ca 2+ transient decay time constant (τ) was also significantly prolonged in aged WT atria ( Figure 3B , lower) compared with young controls. Simultaneous optical recordings of intracellular Ca 2+ and V m showed significantly increased spatiotemporal heterogeneity between the 2 signals (Δt Vm−Ca ) in aged WT atria compared with young controls (Online Figure  IIIA and IIIB). This increased heterogeneity of Δt Vm−Ca in the aged atrium is arrhythmogenic 36 and aligned with the higher frequency of diastolic Ca 2+ waves ( Figure 3A and 3B).
The contribution of JNK activation to the abnormal arrhythmogenic Ca 2+ handling in the absence of aging was explored by treating young WT mice with a JNK activator, anisomycin. 7, 8 In young WT hearts, anisomycin treatment dramatically increased pacing-induced AF ( Figure 3C and 3D). It also increased spontaneous and postpacing Ca 2+ waves, although Ca 2+ transient decay was prolonged (versus sham controls; Figure 3E and 3F). This is likely the same action of age-associated JNK activation in WT aged atria (Figures 2A through 2D, 3A, and 3B). To further assess JNK-specific action of anisomycin, we applied this agent to JNK2KO mice. We found that anisomycin-treated JNK2KO mice did not show aberrant Ca 
JNK Activation and Abnormal Diastolic Ca
2+
Handling
We and others have previously shown that increased diastolic SR Ca 2+ release causes abnormal ectopic activities, which can lead to arrhythmogenesis in diseased hearts. 17, 37, 38 We monitored diastolic SR Ca 2+ release using the tetracainesensitive SR Ca 2+ leak protocol. 17 SR Ca 2+ leak was elevated in aged mouse atrial myocytes ( Figure 4A ) compared with young controls. The JNK2 inhibitor JNK2I-IX completely abolished this elevation. Confluent monolayers of HL-1 myocytes recapitulate in situ many genotypic and electric cardiac phenotypes, including the cell-cell interactions present in the heart. 8, 26 Intracellular Ca 2+ handling in HL-1 myocytes was leak was also demonstrated in anisomycin-treated (24 hours) atrial myocytes isolated from young rabbits (Online Figure  IVD) . Together, our results indicate that JNK activation drives abnormal diastolic SR Ca 2+ leak.
In addition, JNK activation also increased SR Ca 2+ content in both freshly isolated aged mouse atrial myocytes and anisomycin-treated cultured HL-1 myocytes compared with controls. This SR Ca 2+ overload was eliminated by JNK2 inhibition using JNK2I-IX ( Figure 4D and 4E). The systolic Ca 2+ transient amplitude was not changed by JNK activation ( Figure 4F ). However, JNK activation prolonged the Ca 2+ transient decay time constant, but not if JNK2 was inhibited ( Figure 4G ). We also assessed the contribution of NCX (Na + /Ca 2+ exchanger) by measuring the Ca 2+ decay rate of caffeine-induced Ca 2+ transients. This decay rate was not altered by JNK activation (Online Figure IVE) . To test JNK2 isoform specificity further, we applied an adenoviral dominant-negative approach to HL-1 myocytes (Online Figure VA through VD) . JNK2dn (dominant-negative JNK2) abolished the anisomycin-evoked Ca 2+ mishandling phenotype, whereas JNK1dn (dominant-negative JNK1) did not ( Figure 4H through 4J) . This confirms that the JNK action on diastolic SR Ca 2+ leak and overload is indeed JNK2 specific.
Elevated SR Ca 2+ diastolic leak implies dysfunction of the SR Ca 2+ release channels (RyR2). 39 Single RyR2 channel function was assessed by fusing heavy mouse SR microsomes into artificial lipid bilayers. 40 Anisomycin application significantly increased RyR2 open probability (P o ; RyR2 cytosolic Ca 2+ sensitivity) but not when a JNK2 inhibitor was present ( Figure 4K and 4L) . The anisomycin action on P o was also prevented when either alkaline phosphatases or CaMKII inhibitor KN93 was present ( Figure 4L ; Online Figure VIA) . The anisomycin action on RyR2 P o was also confirmed in human RyR channels (Online Figure VIB) . The JNK-associated action on RyR2 P o explains the increased diastolic SR Ca 2+ leak observed in atrial myocytes after JNK2 activation. The KN93 results imply that CaMKII has a role in linking JNK activation and RyR dysfunction. There was no additional JNK or CaMKII added to the SR vesicles, so the isolated RyR2s must have been associated with endogenous JNK and CaMKII. This was verified by measuring the component proteins of heavy SR microsomes (Online Figure VIC ). An intriguing possibility is that JNK activation may promote CaMKII-dependent phosphorylation of RyR2.
JNK2 and CaMKII Crosstalk in Abnormal Ca
2+
Activities and AF Susceptibility
CaMKII activation results in the phosphorylation of various SR Ca 2+ handling proteins (eg, RyR2 and PLB [phospholamban]) and is proarrhythmic in diseased hearts. 17 Blocking of CaMKII function seems to interrupt JNK-to-RyR2 signaling (Results). Immunoblotting revealed that activation of both CaMKII and JNK (ie, CaMKII-P and JNK-P) increased with age in human atria ( Figure 5A ). This trend persisted when CaMKII-P was normalized to total CaMKIIδ proteins (Online Figure IB) . This JNK/CaMKII relationship was also present in aged rabbit atria and anisomycin-treated young rabbit atria ( Figure 5B and 5C ). The CaMKIIdependent phosphorylation of the RyR2 (RyR2815-P) and PLB (PLB17-P [phosphorylated PLB at Thr17]) proteins were assessed. Aged rabbit atria and young anisomycintreated rabbit atria had elevated CaMKII-P and JNK-P levels and increased RyR2815-P (normalized to total RyR2) and PLB17-P levels (normalized to SERCA2 [sarco/endoplasmic reticulum Ca 2+ -ATPase 2]; Figure 5B and 5C). In contrast, NCX and SERCA were unaltered, and there was no change in PKA (protein kinase A)-dependent RyR2 and PLB phosphorylation (RyR2809-P and PLB16-P [phosphorylated PLB at Ser16]; Online Figure VIIB and VIIC) . We did analogous testing in mouse models. A similar outcome was obtained in tamoxifen-induced MKK7D mouse atria with its constitutive JNK activation (Online Figure VIIA) . In JNK2KO young atria, anisomycin treatment did not enhance CaMKII-P or increase the levels of RyR2815-P and PLB17-P ( Figure 5D through 5F) . Also, the PKA-mediated phosphorylation of RyR2809 and PLB16 remained at a level comparable to sham controls and anisomycin-treated WT mouse atria ( Figure 5E and 5F). These control atria had similar JNK2 protein levels. JNK2KO atria had a normal JNK1 level but only trace amounts of JNK2 (Online Figure IIIC and IIID). In aged JNK2KO mouse atria with a long-term JNK2 ablation, there was dramatically reduced CaMKII activation ( Figure 6A ). Likewise, there was dramatically reduced CaMKII activation in aged WT atria that were treated with JNK2I-IX for 10 days ( Figure 6B ). These results indicate that atrial JNK2 activation results in phosphorylation of the CaMKII protein and in turn CaMKII-dependent phosphorylation of RyR2 and PLB.
We also explored the JNK/CaMKII interaction in AC3-I mice, which have cardiac-specific expression of a CaMKII peptide inhibitor. 21 In young AC3-I atria, anisomycin treatment did not enhance AF susceptibility or abnormal Ca 2+ waves in AC3-I atria ( Figure 6C and 6D) . These AC3-I atria had substantially activated JNK but little (if any) CaMKII activation ( Figure 6E ). Together, these results imply that CaMKII activation may be required for JNK-driven arrhythmogenic activities. To test this, we pretreated HL-1 myocytes with the CaMKII inhibitor KN93 or its inactive congener (KN92). The CaMKII inhibition (KN93) eliminated the expected increase in anisomycin-evoked diastolic Ca 2+ leak and Ca 2+ transient decay time constant ( Figure 6F and Online Figure VIIIA) . In contrast, the KN92 pretreatment (leaving CaMKII function intact) did neither. In HL-1 myocytes, JNK2 inhibition, using either a dominant-negative approach or the JNK2 inhibitor JNKK2I-IX, substantially reduced anisomycin-driven CaMKII activation in HL-1 myocytes ( Figure 7A through 7C) . Moreover, coinfection of HL-1 myocytes with adenovirus JNK2 and constitutively activated adenovirus MKK7D to increase JNK2 activation levels resulted in significantly increased CaMKII-P (Online Figure VIIIB) . In contrast, coinfected adenovirus JNK1 and adenovirus MKK7D did not alter CaMKII-P levels. Evidence of successful adenoviral infection is shown in Online Figure VE JNK2 isoform-specific action on CaMKII activation was also confirmed in isolated young rabbit atrial myocytes (Online Figure VIIIC) .
JNK2 Activates CaMKII
Next, we found that a JNK2-specific antibody pulled down the CaMKII protein from human atrial homogenates Figure 5 . Activated JNK2 (c-Jun N-terminal kinase isoform 2) leads to enhanced CaMKII (Ca 2+ /calmodulin-dependent kinase II) activation and promotes CaMKII-dependent phosphorylation of sarcoplasmic reticulum (SR) Ca 2+ handling proteins. A, Example images and pooled immunoblotting data showing that significantly increased CaMKII-P is positively correlated with enhanced JNK activation in human atria with increasing age. B, C, Representative images and summarized data showing that markedly increased CaMKII-P in JNK activated atria from aged rabbits and anisomycin-treated young (Yg) rabbits. And, this is linked to enhanced CaMKII-dependent phosphorylation of RyR2815 (RyR2815-P) and PLB17 (phospholamban; PLB17-P [phosphorylated PLB at Thr17]). D, Immunoblotting results suggest that enhanced JNK-P (phosphorylated JNK) is associated with enhanced CaMKII, but CaMKII activation in JNK2 knockout (KO) mice treated with anisomycin (Aniso) is significantly reduced compared with wild-type (WT) mice treated with Aniso. E, F, JNK2KO (JNK2 knockout) mouse atria attenuated CaMKII-dependent phosphorylation of RyR2815 and PLB17 (RyR2815-P, PLB17-P) compared with that of anisomycin-treated WT mice, although RyR2809 and PLB16 (phosphorylated PLB at Ser16) phosphorylation levels (RyR2809-P, PLB16-P) were unchanged. A.U. indicates arbitrary unit; and RyR, ryanodine receptor.
( Figure 7D ), where the CaMKII was phosphorylated in a JNK2 dose-dependent manner ( Figure 7E ). The added JNK2 was the pure active hJNK (human full-length JNK2) protein. These hJNK2 proteins were incubated with pure hCaMKII (full-length human CaMKII proteins; ; without Ca 2+ /calmodulin present), and this also resulted in JNK2
dose-dependent phosphorylation of hCaMKII ( Figure 7F ). To further explore the JNK2/CaMKII interaction, we transfected HEK293 cells with CaMKII-WT or CaMKII-T286A HA-tagged vectors. The expressed CaMKII proteins were immunoprecipitated using an HA antibody and then incubated with hJNK2. The CaMKII-WT, not the CaMKII-T286A, vivo treatment) reversed the CaMKII activation to the baseline of young hearts compared with markedly increased CaMKII-P in untreated aged mice. C, Representative electrograms (EGs) of burst pacing followed by selfreversion to sinus rhythm (no arrhythmia induced) in anisomycin-treated (Aniso) AC3-I mice and AC3-I-sham control mice (n=0/6, 0/6). This suggests that CaMKII inhibition in AC3-I mice prevents Aniso-induced atrial arrhythmias. D, Summarized data suggest that CaMKII inhibition in AC3-I mice completely abolished Aniso-induced aberrant atrial Ca 2+ waves and prolonged τ of Ca 2+ decay. E, Immunoblotting images of attenuated activated CaMKII in AC3-I mice, whereas Aniso-induced JNK activation remains increased. F, Summarized data of diastolic sarcoplasmic reticulum (SR) Ca 2+ leak in KN93+Aniso (KN93+A) treated and KN92+Aniso (KN92+A) treated HL-1 myocytes compared with sham controls (sham). SRh indicates sinus rhythm.
protein was phosphorylated by the hJNK2 (Figure 7G ). The ADP-Glo kinase phosphorylation assay was used to assess ATP consumption during the phosphorylation reaction. A significant level of hJNK2 phosphorylation of CaMKII-WT, not CaMKII-T286A, was detected ( Figure 7H ). Although we cannot exclude the possibility of JNK action on other phosphorylation sites of CaMKII, our results indicate that JNK2 directly activates the CaMKII protein.
Aging increases oxidative stress, 11, 41 and this can also activate CaMKII. 42 To test the contribution of oxidation to CaMKII activation, we used a mutated CaMKII activity biosensor called camui-vv that lacks the oxidation-sensitive Met280/281 sites but still has the key Thr286 autophosphorylation site. 34 We measured camui-vv FRET in anisomycin-treated (24 hours) rabbit atrial myocytes and found significantly increased CaMKII activity ( Figure 7I ). To corroborate this result, we pretreated HL-1 myocytes with anti-oxidant N-acetyl-L-cysteine and found that this did not alter anisomycin enhanced CaMKII-P status (Online Figure VIIID) . These results suggest that the JNK2-driven increase in CaMKII activation can occur in the absence of CaMKII oxidation. 
Discussion
We discovered that JNK signaling is associated with abnormal Ca 2+ activities and enhanced AF propensity in the aged heart. Our finding reveals for the first time that the JNK2 isoform directly activates CaMKII. The activated CaMKII in turn enhances RyR2-mediated SR Ca 2+ leak, enhancing AF propensity ( Figure 8 ). This is very likely an important pathway linking cellular stresses (eg, aging) to abnormal diastolic Ca 2+ activities. JNK activation has been observed in various cardiovascular diseases associated with a dramatically increased AF propensity, including myocardial infarction and HF. 5, 8, 10 AF, myocardial infarction, and HF frequently occur together in the aging population. [2] [3] [4] However, the underlying mechanisms of AF arrhythmogenic substrate development in aged (but otherwise normal) hearts remain incompletely understood. Our current study revealed a link between JNK activation and enhanced arrhythmic susceptibility in human atria with increasing age but preserved cardiac function and no history of AF or any major cardiovascular diseases. Moreover, the striking antiarrhythmic effects of JNK inhibition in both aged animal and young animal JNK models strongly support the causal link between JNK and AF propensity.
One might argue that atrial structural remodeling could be another contributing proarrhythmic factor. Indeed, patchy fibrosis and generally more interstitial fibrosis is commonly associated with cardiovascular diseases like myocardial infarction, HF, and diabetic cardiomyopathy. However, we and others have reported that there is no evidence of age-associated structural remodeling in the aged rabbit and human atria without a history of coexisting cardiovascular disease or AF. 8, 30, 43 Here, all aged animals and JNK challenged young animals showed preserved cardiac function and normal interstitial fibrosis level. Multiple types of cells can be involved in arrhythmogenic remodeling and AF development. Our studies include cellular Ca 2+ imaging in isolated atrial myocytes and RyR2 single-channel recordings where cell identity is not an issue. And, our results in whole animals, isolated hearts, intact atria, atrial myocytes, and single RyR2 channels are consistent across this broad experimental spectrum. Thus, our conclusion that there is a critical proarrhythmogenic action of JNK-mediated CaMKII activation in atrial myocytes is well supported. In addition to JNK, p38 is another major member of the stress response kinase MAPK (MAP kinase) family. 44 In response to stress stimuli, the actions of JNK and p38 are dependent on cellular context. For example, JNK and p38 have opposite functions (activation or suppression) in cellular senescence. 45, 46 This is in agreement with our previous findings of unchanged p38 in both aged atria 7, 8 and in long-term anisomycin-treated atrial myocytes (data not shown). Although possible contributions of other MAPKs remain to be investigated, our results strongly point to JNK having a critical role in promoting atrial arrhythmias.
The JNK isoforms are generally targeted to distinct functions. 47 In the heart, JNK1 is linked to helping preserve cardiac function and promoting apoptosis during ischemiareperfusion in myocardial infarction hearts. 47 However, to our knowledge, the JNK2 contribution to normal or pathological heart function is unknown to date. Our data show that JNK2 activation is involved in driving SR Ca 2+ mishandling and thus enhancing AF propensity. This JNK2 action was not only present in aged hearts but also occurred in young animals challenged by JNK activation. Genetic JNK2 depletion or JNK2-specific inhibition reduced arrhythmogenicity in aged and young animal models. This implies that this pathway is not a specific ramification of age, but instead is ever-present and thus available to respond to cellular stresses. Specifically, activated JNK2 boosts SR Ca 2+ handling, and this enhances AF propensity in the absence of coexisting cardiovascular disease.
Another novel finding here is our identification of a unique example of kinase pathway crosstalk as JNK2 directly activates CaMKII to drive the pathology. We and others have previously reported that CaMKII phosphorylation of Ca 2+ handling proteins is a key proarrhythmic factor. 17 48 from cross-bred CaMKII-delta overexpression and PLB KO mice are also consistent with this outcome. We are aware that the CaMKII inhibitor KN93 used in the current studies may have off-target effects. However, we have also used the AC3-I mice (cardiac overexpression of CaMKII inhibitory peptide) and AIP in RyR channel measurement to confirm the action of CaMKII inhibition in JNK-driven abnormal Ca 2+ activities in intact atria. The results were consistent with the rescue action of CaMKII inhibition using KN93 or JNK inhibition in diastolic SR Ca 2+ leak in myocytes and RyR channel activities. SR Ca 2+ leak, uptake, and load are increased in paroxysmal AF, but CaMKII and RyR2 phosphorylation status have been reported to be unchanged. 49 The role of CaMKIIdependent SR dysfunction in AF is clearly complex. Our target here was to define JNK contribution in arrhythmic Ca 2+ handling in aged atrium in the absence of AF history. Ageassociated atrial arrhythmogenicity may or may not be analogous to that in paroxysmal or chronic AF situations. However, Li et al 50 have reported JNK activation in a tachypacing canine AF/HF model. Although the contribution of JNK in sustained AF clearly requires further investigation, we present compelling results that show age-associated JNK activation drives CaMKII-dependent atrial arrhythmogenicity via promotion of RyR2-mediated Ca 2+ leak and this can be avoided by limiting JNK2 function. Suppression of CaMKII function is known to mitigate arrhythmias and various heart diseases in animal models provoking a great deal of interest in development of CaMKII inhibitors as possible antiarrhythmic therapeutic agents. 23 We have revealed a novel example of a JNK2/ CaMKII link where JNK2 directly activates CaMKII to drive arrhythmic remodeling.
Whether there are other mechanisms of JNK-driven Ca
2+
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